DEA is placing mitragynine pseudoindoxyl (MP) into Schedule I. States that keep kratom legal now have to distinguish ordinary kratom from commercial products containing a federally controlled substance.
That leaves lawmakers with two choices: build and continuously fund a testing-and-enforcement system capable of finding MP in retail kratom products—or adopt the simpler rule and prohibit kratom sales.
That finding changes the scale of the policy question. This is not simply a matter of finding an occasional package openly marketed as pseudoindoxyl. Researchers detected MP across a commercial sample set while labeling frequently failed to disclose it.
A 2026 mass-spectrometry study examined authenticated kratom material and commercial products. The researchers did not confirm MP in authenticated kratom leaf—but they did confirm it in 8 of 9 tablets and 2 capsules.
The policy problem: a package can say “kratom,” “natural,” or “botanical.” None of those words establishes whether the finished product contains MP.
Certificates of analysis supplied for named commercial kratom products show why the issue matters at the retail counter.
Accurate MP identification requires appropriate analytical methods. Closely related kratom alkaloids can produce overlapping signals, and DEA itself notes that these substances require specific methods and instrumentation for accurate identification.
1. Are retail kratom products currently being tested for MP?
2. Who independently samples products and verifies manufacturer COAs?
3. What validated analytical method and detection limit are required?
4. What happens statewide when a lot tests positive for MP?
5. Who pays for continuous sampling, testing, recalls and enforcement?
Maintaining a partially legal kratom market means distinguishing permissible products from products containing Schedule I MP—across changing formulations, manufacturers, lots and retailers.
A prohibition draws a line that does not require a laboratory result at the point of sale:
No alkaloid calculations. No retailer interpreting laboratory reports. No perpetual fight over whether a product is “natural.” No state testing infrastructure simply to determine which kratom product at a gas station may contain a Schedule I substance.
DEA did not schedule ordinary kratom leaf through this action. That distinction matters. But DEA did schedule MP; one 2026 study detected MP in 33 of 35 commercial kratom products, another confirmed it in 8 of 9 tablets and two capsules, and accurate identification requires laboratory analysis.
If preserving retail kratom sales requires continuous testing, validated mass-spectrometry methods, independent sampling, lot tracking, recalls and enforcement, lawmakers should ask whether the easier public-policy choice is simply to stop the sale.
